Baseline characteristics of patients with DLBCL alone, concurrent DLBCL and FL, and concurrent DLBCL and other indolent NHL
| . | DLBCL alone, n . | % . | Concurrent DLBCL and FL, n . | % . | P, vs DLBCL alone . | Concurrent DLBCL and other indolent NHL, n . | % . | P, vs DLBCL alone . |
|---|---|---|---|---|---|---|---|---|
| Age | .39 | .28 | ||||||
| ≤60 y | 490 | 42.5 | 51 | 46.8 | 22 | 35.5 | ||
| >60 y | 663 | 57.5 | 58 | 53.2 | 40 | 64.5 | ||
| Sex | .10 | .55 | ||||||
| Male | 658 | 57.1 | 71 | 65.1 | 33 | 53.2 | ||
| Female | 495 | 42.9 | 38 | 34.9 | 29 | 46.8 | ||
| ECOG PS | .80 | .51 | ||||||
| <2 | 946 | 82.2 | 89 | 83.2 | 53 | 85.5 | ||
| ≥2 | 205 | 17.8 | 18 | 16.8 | 9 | 14.5 | ||
| Missing | 2 | 2 | ||||||
| Ann Arbor stage | .12 | <.01 | ||||||
| I-II | 441 | 38.2 | 33 | 30.6 | 5 | 8.2 | ||
| III-IV | 712 | 61.8 | 75 | 69.4 | 56 | 91.8 | ||
| Missing | 1 | 1 | ||||||
| LDH | <.01 | .37 | ||||||
| Normal | 443 | 42.3 | 60 | 63.8 | 28 | 48.3 | ||
| Elevated | 604 | 57.7 | 34 | 36.2 | 30 | 51.7 | ||
| Missing | 106 | 15 | 4 | |||||
| Extranodal sites | .38 | .16 | ||||||
| ≤1 | 922 | 80.0 | 91 | 83.5 | 45 | 72.6 | ||
| >1 | 231 | 20.0 | 18 | 16.5 | 17 | 27.4 | ||
| IPI score | <.01 | .09 | ||||||
| 0-1 | 382 | 33.1 | 39 | 35.8 | 11 | 17.7 | ||
| 2 | 317 | 27.5 | 46 | 42.2 | 22 | 35.5 | ||
| 3 | 308 | 26.7 | 15 | 13.8 | 19 | 30.6 | ||
| 4-5 | 146 | 12.7 | 9 | 8.3 | 10 | 16.1 | ||
| Bone marrow involvement | — | — | ||||||
| DLBCL | 156 | 13.5 | 9 | 8.3 | 2 | 3.2 | ||
| Indolent NHL | 0 | 0 | 28 | 25.7 | 52 | 83.9 | ||
| No involvement | 900 | 78.1 | 65 | 59.6 | 7 | 11.3 | ||
| Not done/missing | 97 | 8.4 | 7 | 6.4 | 1 | 1.6 | ||
| Cell of origin | <.01 | .06 | ||||||
| GCB | 490 | 61.8 | 79 | 92.9 | 21 | 47.7 | ||
| Non-GCB | 303 | 38.2 | 6 | 7.1 | 23 | 52.3 | ||
| Missing | 360 | 24 | 18 |
| . | DLBCL alone, n . | % . | Concurrent DLBCL and FL, n . | % . | P, vs DLBCL alone . | Concurrent DLBCL and other indolent NHL, n . | % . | P, vs DLBCL alone . |
|---|---|---|---|---|---|---|---|---|
| Age | .39 | .28 | ||||||
| ≤60 y | 490 | 42.5 | 51 | 46.8 | 22 | 35.5 | ||
| >60 y | 663 | 57.5 | 58 | 53.2 | 40 | 64.5 | ||
| Sex | .10 | .55 | ||||||
| Male | 658 | 57.1 | 71 | 65.1 | 33 | 53.2 | ||
| Female | 495 | 42.9 | 38 | 34.9 | 29 | 46.8 | ||
| ECOG PS | .80 | .51 | ||||||
| <2 | 946 | 82.2 | 89 | 83.2 | 53 | 85.5 | ||
| ≥2 | 205 | 17.8 | 18 | 16.8 | 9 | 14.5 | ||
| Missing | 2 | 2 | ||||||
| Ann Arbor stage | .12 | <.01 | ||||||
| I-II | 441 | 38.2 | 33 | 30.6 | 5 | 8.2 | ||
| III-IV | 712 | 61.8 | 75 | 69.4 | 56 | 91.8 | ||
| Missing | 1 | 1 | ||||||
| LDH | <.01 | .37 | ||||||
| Normal | 443 | 42.3 | 60 | 63.8 | 28 | 48.3 | ||
| Elevated | 604 | 57.7 | 34 | 36.2 | 30 | 51.7 | ||
| Missing | 106 | 15 | 4 | |||||
| Extranodal sites | .38 | .16 | ||||||
| ≤1 | 922 | 80.0 | 91 | 83.5 | 45 | 72.6 | ||
| >1 | 231 | 20.0 | 18 | 16.5 | 17 | 27.4 | ||
| IPI score | <.01 | .09 | ||||||
| 0-1 | 382 | 33.1 | 39 | 35.8 | 11 | 17.7 | ||
| 2 | 317 | 27.5 | 46 | 42.2 | 22 | 35.5 | ||
| 3 | 308 | 26.7 | 15 | 13.8 | 19 | 30.6 | ||
| 4-5 | 146 | 12.7 | 9 | 8.3 | 10 | 16.1 | ||
| Bone marrow involvement | — | — | ||||||
| DLBCL | 156 | 13.5 | 9 | 8.3 | 2 | 3.2 | ||
| Indolent NHL | 0 | 0 | 28 | 25.7 | 52 | 83.9 | ||
| No involvement | 900 | 78.1 | 65 | 59.6 | 7 | 11.3 | ||
| Not done/missing | 97 | 8.4 | 7 | 6.4 | 1 | 1.6 | ||
| Cell of origin | <.01 | .06 | ||||||
| GCB | 490 | 61.8 | 79 | 92.9 | 21 | 47.7 | ||
| Non-GCB | 303 | 38.2 | 6 | 7.1 | 23 | 52.3 | ||
| Missing | 360 | 24 | 18 |
—, not calculated; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase.